vs
Alkermes plc.（ALKS）与RBC Bearings INC（RBC）财务数据对比。点击上方公司名可切换其他公司
RBC Bearings INC的季度营收约是Alkermes plc.的1.2倍（$461.6M vs $384.5M），RBC Bearings INC净利率更高（14.6% vs 12.8%，领先1.8%），RBC Bearings INC同比增速更快（17.0% vs -10.6%），Alkermes plc.自由现金流更多（$170.0M vs $99.1M），过去两年RBC Bearings INC的营收复合增速更高（5.6% vs 4.8%）
Alkermes plc是一家全产业链布局的生物制药企业，专注于精神障碍与神经系统疾病相关药物的研发。公司1987年由迈克尔·沃尔创立，2011年9月与原Élan集团旗下的药物制剂及生产部门Elan Drug Technologies合并，总部位于都柏林，在马萨诸塞州沃尔瑟姆设有研发中心，俄亥俄州威尔明顿建有生产基地。
该文本实际介绍的并非RBC Bearings，而是美国多佛公司。多佛是一家工业产品综合制造商，1955年成立，总部位于伊利诺伊州当纳斯格罗夫。2021年其业务分为五大板块：工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术，是标普500成分股，在纽约证券交易所上市。
ALKS vs RBC — 直观对比
营收规模更大
RBC
是对方的1.2倍
$384.5M
营收增速更快
RBC
高出27.6%
-10.6%
净利率更高
RBC
高出1.8%
12.8%
自由现金流更多
ALKS
多$70.9M
$99.1M
两年增速更快
RBC
近两年复合增速
4.8%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $384.5M | $461.6M |
| 净利润 | $49.3M | $67.4M |
| 毛利率 | 88.0% | 44.3% |
| 营业利润率 | 15.1% | 22.3% |
| 净利率 | 12.8% | 14.6% |
| 营收同比 | -10.6% | 17.0% |
| 净利润同比 | -66.3% | 16.4% |
| 每股收益（稀释后） | $0.29 | $2.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALKSRBC
| Q4 25 | $384.5M | $461.6M | ||
| Q3 25 | $394.2M | $455.3M | ||
| Q2 25 | $390.7M | $436.0M | ||
| Q1 25 | $306.5M | $437.7M | ||
| Q4 24 | $430.0M | $394.4M | ||
| Q3 24 | $378.1M | $397.9M | ||
| Q2 24 | $399.1M | $406.3M | ||
| Q1 24 | $350.4M | $413.7M |
净利润ALKSRBC
| Q4 25 | $49.3M | $67.4M | ||
| Q3 25 | $82.8M | $60.0M | ||
| Q2 25 | $87.1M | $68.5M | ||
| Q1 25 | $22.5M | $72.7M | ||
| Q4 24 | $146.5M | $57.9M | ||
| Q3 24 | $92.4M | $54.2M | ||
| Q2 24 | $91.4M | $61.4M | ||
| Q1 24 | $36.8M | — |
毛利率ALKSRBC
| Q4 25 | 88.0% | 44.3% | ||
| Q3 25 | 86.9% | 44.1% | ||
| Q2 25 | 87.3% | 44.8% | ||
| Q1 25 | 83.9% | 44.2% | ||
| Q4 24 | 85.6% | 44.3% | ||
| Q3 24 | 83.3% | 43.7% | ||
| Q2 24 | 84.6% | 45.3% | ||
| Q1 24 | 83.3% | 43.1% |
营业利润率ALKSRBC
| Q4 25 | 15.1% | 22.3% | ||
| Q3 25 | 22.6% | 21.5% | ||
| Q2 25 | 23.8% | 23.2% | ||
| Q1 25 | 4.5% | 23.0% | ||
| Q4 24 | 37.8% | 21.7% | ||
| Q3 24 | 27.7% | 21.6% | ||
| Q2 24 | 27.5% | 24.0% | ||
| Q1 24 | 12.4% | 22.8% |
净利率ALKSRBC
| Q4 25 | 12.8% | 14.6% | ||
| Q3 25 | 21.0% | 13.2% | ||
| Q2 25 | 22.3% | 15.7% | ||
| Q1 25 | 7.3% | 16.6% | ||
| Q4 24 | 34.1% | 14.7% | ||
| Q3 24 | 24.4% | 13.6% | ||
| Q2 24 | 22.9% | 15.1% | ||
| Q1 24 | 10.5% | — |
每股收益（稀释后）ALKSRBC
| Q4 25 | $0.29 | $2.13 | ||
| Q3 25 | $0.49 | $1.90 | ||
| Q2 25 | $0.52 | $2.17 | ||
| Q1 25 | $0.13 | $2.33 | ||
| Q4 24 | $0.88 | $1.82 | ||
| Q3 24 | $0.55 | $1.65 | ||
| Q2 24 | $0.53 | $1.90 | ||
| Q1 24 | $0.21 | $1.92 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.6M | $107.6M |
| 总债务越低越好 | — | $990.2M |
| 股东权益账面价值 | $1.8B | $3.3B |
| 总资产 | $2.5B | $5.1B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资ALKSRBC
| Q4 25 | $388.6M | $107.6M | ||
| Q3 25 | $616.4M | $91.2M | ||
| Q2 25 | $521.2M | $132.9M | ||
| Q1 25 | $399.8M | $36.8M | ||
| Q4 24 | $291.1M | — | ||
| Q3 24 | $396.3M | — | ||
| Q2 24 | $535.1M | $76.8M | ||
| Q1 24 | $420.8M | $63.5M |
总债务ALKSRBC
| Q4 25 | — | $990.2M | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $915.6M | ||
| Q1 25 | — | $920.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.2B |
股东权益ALKSRBC
| Q4 25 | $1.8B | $3.3B | ||
| Q3 25 | $1.7B | $3.2B | ||
| Q2 25 | $1.6B | $3.1B | ||
| Q1 25 | $1.5B | $3.0B | ||
| Q4 24 | $1.5B | $2.9B | ||
| Q3 24 | $1.3B | $2.9B | ||
| Q2 24 | $1.3B | $2.8B | ||
| Q1 24 | $1.3B | $2.8B |
总资产ALKSRBC
| Q4 25 | $2.5B | $5.1B | ||
| Q3 25 | $2.3B | $5.1B | ||
| Q2 25 | $2.3B | $4.8B | ||
| Q1 25 | $2.1B | $4.7B | ||
| Q4 24 | $2.1B | $4.7B | ||
| Q3 24 | $2.2B | $4.7B | ||
| Q2 24 | $2.2B | $4.7B | ||
| Q1 24 | $2.1B | $4.7B |
负债/权益比ALKSRBC
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $170.1M | $122.1M |
| 自由现金流经营现金流 - 资本支出 | $170.0M | $99.1M |
| 自由现金流率自由现金流/营收 | 44.2% | 21.5% |
| 资本支出强度资本支出/营收 | 0.0% | 5.0% |
| 现金转化率经营现金流/净利润 | 3.45× | 1.81× |
| 过去12个月自由现金流最近4个季度 | $480.3M | — |
8季度趋势，按日历期对齐
经营现金流ALKSRBC
| Q4 25 | $170.1M | $122.1M | ||
| Q3 25 | $101.7M | $88.4M | ||
| Q2 25 | $150.2M | $120.0M | ||
| Q1 25 | $98.8M | — | ||
| Q4 24 | $190.4M | $84.0M | ||
| Q3 24 | $81.6M | — | ||
| Q2 24 | $146.0M | $97.4M | ||
| Q1 24 | $21.1M | — |
自由现金流ALKSRBC
| Q4 25 | $170.0M | $99.1M | ||
| Q3 25 | $84.4M | $71.7M | ||
| Q2 25 | $137.2M | $104.3M | ||
| Q1 25 | $88.7M | — | ||
| Q4 24 | $180.6M | $73.6M | ||
| Q3 24 | $73.3M | — | ||
| Q2 24 | $138.9M | $88.4M | ||
| Q1 24 | $12.8M | — |
自由现金流率ALKSRBC
| Q4 25 | 44.2% | 21.5% | ||
| Q3 25 | 21.4% | 15.7% | ||
| Q2 25 | 35.1% | 23.9% | ||
| Q1 25 | 28.9% | — | ||
| Q4 24 | 42.0% | 18.7% | ||
| Q3 24 | 19.4% | — | ||
| Q2 24 | 34.8% | 21.8% | ||
| Q1 24 | 3.6% | — |
资本支出强度ALKSRBC
| Q4 25 | 0.0% | 5.0% | ||
| Q3 25 | 4.4% | 3.7% | ||
| Q2 25 | 3.3% | 3.6% | ||
| Q1 25 | 3.3% | 3.2% | ||
| Q4 24 | 2.3% | 2.6% | ||
| Q3 24 | 2.2% | 4.1% | ||
| Q2 24 | 1.8% | 2.2% | ||
| Q1 24 | 2.4% | — |
现金转化率ALKSRBC
| Q4 25 | 3.45× | 1.81× | ||
| Q3 25 | 1.23× | 1.47× | ||
| Q2 25 | 1.72× | 1.75× | ||
| Q1 25 | 4.40× | — | ||
| Q4 24 | 1.30× | 1.45× | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 1.60× | 1.59× | ||
| Q1 24 | 0.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
